[1]
|
赵华, 王凯, 王鸿雁, 郑建杰. 心脏副神经节瘤1例并文献复习[J]. 诊断病理学杂志, 2020, 27(8): 564-566+572.
|
[2]
|
Thompson, L.D.R. (2006) World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. ENT Journal, 85, 427-437. https://doi.org/10.1177/014556130608500201
|
[3]
|
刘彤华, 诊断病理学[M]. 第3版. 北京: 人民卫生出版社, 428-429.
|
[4]
|
方三高, 魏建国, 周晓军. WHO (2017)肾上腺肿瘤分类解读[J]. 诊断病理学杂志, 2018, 25(12): 801-806.
|
[5]
|
Thompson, L.D.R. (2002) Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign from Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases. The American Journal of Surgical Pathology, 26, 551-566. https://doi.org/10.1097/00000478-200205000-00002
|
[6]
|
Noriko, K., Ryoichi, T., Nae, T., Eiji, I., Takayuki, K., Narihiko, K., Hiromi, R., Yukihiro, I., Akiyo, T., Takeshi, N., Sadayoshi, I., Itaru, K. and Mitsuhide, N. (2014) Pathological Grading for Predicting Metastasis in Phaeochromocytoma and Paraganglioma. Endocrine-Related Cancer, 21, 405-414. https://doi.org/10.1530/ERC-13-0494
|
[7]
|
Niu, F., Li, Y., Lai, F.-F. and Chen, X.-G. (2014) [Research Progress of Hypoxia-Inducible Factor 1 Inhibitors against Tumors]. Acta Pharmaceutica Sinica, 49, 832-836.
|
[8]
|
Peng, S., Zhang, J., Tan, X., Huang, Y., Xu, J., Silk, N., Zhang, D., Liu, Q. and Jiang, J. (2020) The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Frontiers in Endocrinology, 11, Article ID: 586857. https://doi.org/10.3389/fendo.2020.586857
|
[9]
|
Bausch, B., Wellner, U., Bausch, D., et al. (2014) Long-Term Prognosis of Patients with Pediatric Pheochromocytoma. Endocrine-Related Cancer, 21, 17-25. https://doi.org/10.1530/ERC-13-0415
|
[10]
|
Lefebvre, M. and Foulkes, W.D. (2014) Pheochromocytoma and Paraganglioma Syndromes: Genetics and Management Update. Current Oncology, 21, e8-e17. https://doi.org/10.3747/co.21.1579
|
[11]
|
石穿, 曾正陪, 赵大春, 李汉忠, 苗齐, 朱文玲, 陈适, 卢琳, 梁志勇. 琥珀酸脱氢酶B、C免疫组化在鉴别良恶性嗜铬细胞瘤和副神经节瘤中的应用[J]. 中华内分泌代谢杂志, 2018, 34(6): 472-478.
|
[12]
|
Lucinda, G. and James, M.L. (2021) Predicted Succinated Dehydrogenase Subunit Variant Pathogenicity: Why Are SDHB Variants “Bad”? Journal of the Endocrine Society, 5, A71-A72. https://doi.org/10.1210/jendso/bvab048.144
|
[13]
|
车金娜. 潜在恶性嗜铬细胞瘤的临床特征分析及SDHB、SDHD的相关研究[D]: [硕士学位论文]. 青岛: 青岛大学, 2020.
|
[14]
|
Cui, Y., Ma, X., Wang, F., Wang, H., Zhou, T., Chen, S., Tong, A. and Li, Y. (2021) Differences in Clinical Manifestations and Tumor Features between Metastatic Pheochromocytoma/Paraganglioma Patients with and without Germline SDHB Mutation. Endocrine Practice, 27, 348-353. https://doi.org/10.1016/j.eprac.2020.09.015
|
[15]
|
Dahia, P.L.M. (2014) Pheochromocytoma and Paraganglioma Pathogenesis: Learning from Genetic Heterogeneity. Nature Reviews Cancer, 14, 108-119. https://doi.org/10.1038/nrc3648
|
[16]
|
Tarade, D., Robinson, C.M., Lee, J.E. and Ohh, M. (2018) HIF-2α-pVHL Complex Reveals Broad Genotype-Phenotype Correlations in HIF-2α-Driven Disease. Nature Communications, 9, Article No. 3359.
https://doi.org/10.1038/s41467-018-05554-1
|
[17]
|
Xiong, Z., Xiong, W., Xiao, W., Yuan, C., Shi, J., Huang, Y., Wang, C., Meng, X., Chen, Z., Yang, H., Chen, K. and Zhang, X. (2021) NNT-Induced Tumor Cell “Slimming” Reverses the Pro-Carcinogenesis Effect of HIF2a in Tumors. Clinical and Translational Medicine, 11, e264. https://doi.org/10.1002/ctm2.264
|
[18]
|
C. Bellevicine, I. Migliatico, R. Sgariglia, M. Nacchio, E. Vigliar, P. Pisapia, et al. (2020) Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg Alterations in Different Bethesda Diagnostic Categories: A Multicentric Prospective Study on the Validity of the 7-Gene Panel Test in 1172 Thyroid FNAs Deriving from Different Hospitals in South Italy. Cancer Cytopathology, 128, 107-118. https://doi.org/10.1002/cncy.22217
|
[19]
|
Erika, M., Floriana, M., Teresa, T. and Fortunato, C. (2017) Cancer Resistance to Therapies against the EGFR-RAS-RAF Pathway: The Role of MEK. Cancer Treatment Reviews, 53, 61-69. https://doi.org/10.1016/j.ctrv.2016.12.001
|
[20]
|
Vari, S., Pilotto, S., Maugeri-Saccà, M., Ciuffreda, L., Incani, U.C., Falcone, I., et al. (2013) Advances towards the Design and Development of Personalized Non-Small-Cell Lung Cancer Drug Therapy. Expert Opinion on Drug Discovery, 8, 1381-1397. https://doi.org/10.1517/17460441.2013.843523
|
[21]
|
张婷婷, 邓丽玲, 邓明彦, 任艳. 2例多发性内分泌腺瘤病2A型家系临床分析及RET基因突变研究[J]. 四川大学学报(医学版), 2019, 50(5): 757-759.
|
[22]
|
Pan, Y., Hysinger, J.D., Barron, T., Schindler, N.F., Cobb, O., Guo, X., et al. (2021) NF1 Mutation Drives Neuronal Activity-Dependent Initiation of Optic Glioma. Nature, 594, 277-282. https://doi.org/10.1038/s41586-021-03580-6
|
[23]
|
Habulieti, X., Sun, L., Liu, J., Guo, K., Yang, X., Wang, R., Ma, D. and Zhang, X. (2021) Phenotypic and Genetic Characterization of Novel Variant in the NF1 Gene Underlying Neurofibromatosis Type 1 in Five Chinese Families. Science China Life Sciences, 1-4. http://kns.cnki.net/kcms/detail/11.5841.Q.20210513.1311.002.html
https://doi.org/10.1007/s11427-020-1922-3
|
[24]
|
Patel, D., Phay, J.E., Yen, T.W.F., Dickson, P.V., Wang, T.S., Garcia, R., et al. (2020) Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology, 27, 1329-1337.
https://doi.org/10.1245/s10434-020-08220-3
|
[25]
|
卢梦杰. 人源生长抑素II型受体(SSTR2)的结构生物学研究[D]: [博士学位论文]. 上海: 中国科学院大学(中国科学院上海药物研究所), 2019.
|